Induction of nitric oxide synthase (NOS)-2 and production of nitric oxide (NO) are common features of allergic airway disease. Conditions of severe asthma are associated with deficiency of airway S-nitrosothiols, a biological product of NO that can suppress inflammation by S-nitrosylation of the proinflammatory transcription factor, NF-kB. Therefore, restoration of airway S-nitrosothiols might have therapeutic benefit, and this was tested in a mouse model of ovalbumin (OVA)-induced allergic inflammation. Naive or OVAsensitized animals were administered S-nitrosoglutathione (GSNO; 50 ml, 10 mM) intratracheally before OVA challenge and analyzed 48 hours later. GSNO administration enhanced lung tissue S-nitrosothiol levels and reduced NF-kB activity in OVA-challenged animals compared with control animals, but did not lead to significant changes in total bronchoalveolar lavage cell counts, differentials, or mucus metaplasia markers. Administration of GSNO also altered the activation of hypoxia-inducible factor (HIF)-1, leading to HIF-1 activation in naive mice, but suppressed HIF-1 activation in OVA-challenged mice. We assessed the contribution of endogenous NOS2 in regulating NF-kB and/or HIF-1 activation and allergic airway inflammation using NOS2 2/2 mice. Although OVA-induced NF-kB activation was slightly increased in NOS2 2/2 mice, associated with small increases in bronchoalveolar lavage neutrophils, other markers of allergic inflammation and HIF-1 activation were similar in NOS2 2/2 and wildtype mice. Collectively, our studies indicate that instillation of GSNO can suppress NF-kB activation during allergic airway inflammation, but does not significantly affect overall markers of inflammation or mucus metaplasia, thus potentially limiting its therapeutic potential due to effects on additional signaling pathways, such as HIF-1.Keywords: nitric oxide; asthma; S-nitrosothiols; nuclear factor-kB; hypoxia inducible factor21Nitric oxide (NO) is a ubiquitous signaling molecule that is continuously produced within the airways of healthy individuals, primarily originating from constitutive expression of the inducible NO synthase (NOS)-2 (iNOS) within the respiratory epithelium (1, 2). Airway NO production is increased under conditions of infection or inflammation due to induction of NOS2. Indeed, induction of airway NOS2 and increased airway production of NO are common symptoms of allergic asthma, an inflammatory disease of the airways characterized by airway hyperreactivity, smooth muscle thickening, and mucus hypersecretion. Analysis of exhaled human breath has demonstrated higher levels of NO in patients with asthma compared with healthy control subjects, with increases in epithelial NOS2 being the primary site of its production (1, 2). Induction of NOS2 is critical in innate antimicrobial or antiviral host defense, but its contribution in conditions of airway inflammation, including allergic asthma, is still controversial, and includes both pro-and anti-inflammatory properties, based on studies with NOS2 inhibitors...